Drug intelligence / Profile preview

Alphaday

Development stage: Preclinical
Lead developer: Intra Life
Administration: Oral

Overview

**Alphaday** is an oral keto-analogue-of-amino-acids nutritional product listed by Intra Life for nutritional management of chronic kidney disease. Keto-analogues can be transaminated into essential amino acids while contributing less nitrogen than conventional amino-acid supplementation, supporting protein-restricted dietary management intended to reduce nitrogenous-waste generation in chronic kidney disease. The publicly available pipeline entry identifies the product as a suspension but does not specify its individual keto-analogue constituents or doses.

Brand names: Alphaday

Beyond the preview

Go deeper on Alphaday.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphaday.

Explore the full profile